| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Lipids and Lipoproteins |
1
CALAB Research and CALAB Medical Laboratories, S:t Göran Hospital, S-112 81 Stockholm, Sweden.
2
Department of Medicine, Northwest Lipid Research
Laboratories, University of Washington, 2121 N 35th St., Seattle, WA
98103.
3
King Gustaf V Research Institute, Karolinska Institute,
S-10401 Stockholm, Sweden, and ASTRA HÄSSLE AB, S-43183
Mölndal, Sweden.
4
Institute for Medical Statistics, Ullevål Sykehus, P.O.
Box 6, 0407 Oslo 4, Norway.
a Author for correspondence. Fax 46-86673418;
Serum concentrations of apolipoprotein (apo) B and apo A-I were measured from 1985–1996 in a Swedish population sample of 83 112 males and 64 464 females, ages <20 to >80 years, using an automated immunoturbidimetric method calibrated against fresh pools of human serum and commercial calibrators. All values were recalculated in 1997 after calibration against the WHO-IFCC First International Reference Materials. The recalculation factor was 1.059 for apo B, whereas for apo A-I, the correction was: y = 0.989x + 0.101. The total CVs for both apo B and A-I were generally <7%. The mean value (± SD) for apo B was 1.31 ± 0.35 g/L in all males and 1.22 ± 0.36 g/L in all females. The mean apo A-I concentration was 1.36 ± 0.22 g/L in males–10% lower than in females (1.51 ± 0.24 g/L). The mean value of apo B increased up to 60 years of age in males and up to 70 years of age in females. apo A-I concentrations changed only slightly with age in both males and females. apo A-I concentrations among Swedes are nearly identical to those reported recently by two American studies and those obtained in a Finnish population sample. Mean apo B concentrations differ somewhat between the populations but mirror–as expected–differences in total cholesterol concentrations. The highest values were noted in Swedish subjects. The Swedish sample population is, to our knowledge, the largest describing the distribution of apo B and A-I in a general population of adult males and females of all ages determined with procedures standardized and traceable to the WHO-IFCC First International Reference Materials.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  I. Holme, A. H. Aastveit, N. Hammar, I. Jungner, and G. Walldius Lipoprotein components and risk of congestive heart failure in 84 740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS) Eur J Heart Fail, November 1, 2009; 11(11): 1036 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Baca and G. R. Warnick Estimation of LDL-Associated Apolipoprotein B from Measurements of Triglycerides and Total Apolipoprotein B Clin. Chem., May 1, 2008; 54(5): 907 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Axler, J. Ahnstrom, and B. Dahlback An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma J. Lipid Res., August 1, 2007; 48(8): 1772 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Magkos, B. W. Patterson, B. S. Mohammed, S. Klein, and B. Mittendorfer Women Produce Fewer but Triglyceride-Richer Very Low-Density Lipoproteins than Men J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1311 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Moore, E. T. Fung, M. McGuire, C. C. Rabkin, A. Molinaro, Z. Wang, F. Zhang, J. Wang, C. Yip, X.-Y. Meng, et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1641 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhang, R. C. Bast Jr., Y. Yu, J. Li, L. J. Sokoll, A. J. Rai, J. M. Rosenzweig, B. Cameron, Y. Y. Wang, X.-Y. Meng, et al. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer Cancer Res., August 15, 2004; 64(16): 5882 - 5890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Carmena, P. Duriez, and J.-C. Fruchart Atherogenic Lipoprotein Particles in Atherosclerosis Circulation, June 15, 2004; 109(23_suppl_1): III-2 - III-7. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. S Kahn and R. Valdez Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration Am. J. Clinical Nutrition, November 1, 2003; 78(5): 928 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kujiraoka, M. N. Nanjee, T. Oka, M. Ito, M. Nagano, C. J. Cooke, S. Takahashi, W. L. Olszewski, J. S. Wong, I. P. Stepanova, et al. Effects of Intravenous Apolipoprotein A-I/Phosphatidylcholine Discs on LCAT, PLTP, and CETP in Plasma and Peripheral Lymph in Humans Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1653 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Wagner, A. Perez, E. Zapico, and J. Ordonez-Llanos Non-HDL Cholesterol and Apolipoprotein B in the Dyslipidemic Classification of Type 2 Diabetic Patients Diabetes Care, July 1, 2003; 26(7): 2048 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Sniderman, T. Scantlebury, and K. Cianflone Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus Ann Intern Med, September 18, 2001; 135(6): 447 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Havel and P. H. Frost The Role of Non-High-Density Lipoprotein-Cholesterol in Evaluation and Treatment of Lipid Disorders J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2105 - 2108. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
